Scarica l'app Stockscreener
147.90
6.04%
8.42
Dopo l'orario di chiusura:
148.54
0.64
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines rises as FDA clears expanded access pathway for daraxonrasib - Quiver Quantitative
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Revolution Medicines Files Patent Infringement Lawsuit Against Erasca - HarianBasis.co
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity - Insider Monkey
Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This Stock - Yahoo Finance
Jennison Associates LLC Takes $24.31 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines' Pancreatic-Cancer Drug Cleared for Expanded Access - Moomoo
US FDA authorizes early access to Revolution's pancreatic cancer pill - Reuters
Revolution Medicines Advances Pancreatic Cancer Treatment with Daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Gains FDA Approval for Daraxonrasib in Pancreatic Cancer - GuruFocus
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill - Investing.com Canada
Revolution Medicines (RVMD) Advances with FDA Approval for Expan - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
The U.S. Food and Drug Administration (FDA) has issued a "safe to proceed" letter to Revolution Medicines, Inc., approving the initiation of an expanded access program for its investigational drug Daraxonrasib for the treatment of pancreatic cancer patients. - Bitget
Revolution Medicines' cancer drug made available in U.S. - Seeking Alpha
F.D.A. grants early access to Revolution Medicines promising drug Daraxonrasib for pancreatic cancerNYT - marketscreener.com
Revolution Medicines, Inc. $RVMD Shares Bought by Vanguard Group Inc. - MarketBeat
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know - Pancreatic Cancer Action Network
Revolution Medicines Data Updates Refocus Investor Attention On RAS Pipeline Potential - simplywall.st
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - MSN
Revolution Medicines’ Anthony Mancini sells $413k in shares By Investing.com - Investing.com India
Revolution Medicines’ Anthony Mancini sells $413k in shares - Investing.com
Revolution Medicines (RVMD) insider sells 3,120 shares after exercising options - Stock Titan
Revolution Medicines sets May 6 webcast for Q1 results, corporate update - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Universal Beteiligungs und Servicegesellschaft mbH Has $5.23 Million Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines has a market cap of $29 billion and generates no revenue. Here's why its valuation may not be as ridiculous as it seems - MSN
Pictet Asset Management Holding SA Reduces Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Bought by UBS Group AG - MarketBeat
Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - MarketBeat
RVMD Technical Analysis | Trend, Signals & Chart Patterns | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines (RVMD) price target increased by 29.89% to 177.75 - MSN
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
RVMD Stock Rallies As Daraxonrasib Data Ignite Wall Street - StocksToTrade
RVMD Stock Rallies As Daraxonrasib Data Fuels Bullish Re‑Rating - timothysykes.com
Biotech Momentum Sparks Attention Beyond Nasdaq Composite - Kalkine Media
Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates - Yahoo Finance
There’s a Revolution in Cancer. But Can Big Pharma Afford It? - WSJ
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst Upgrade - MarketBeat
RVMD Stock Climbs As Daraxonrasib Data Ignite Street Targets - StocksToTrade
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
High-flying Revolution Medicines threatens to sue a cancer drug competitor with licensed Chinese drug - The Business Journals
[ARS] Revolution Medicines, Inc. SEC Filing - Stock Titan
Revolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at Truist Financial - MarketBeat
Calamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused Pipeline - Yahoo Finance
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
RVMDW Price History for Revolution Medicines WT Stock - Barchart
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Revolution Medicines (NASDAQ: RVMD) outlines 2026 virtual annual meeting votes - Stock Titan
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems - The Motley Fool
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
5.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):